Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
Related Questions
How would you manage incidentally-found prostate cancer on TURP?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
When treating an inoperable urothelial cancer of the renal pelvis, what are your considerations when determining candidacy for SBRT?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
How do you counsel/advise patients when asked to compare ultrahypofractionated radiotherapy with the TULSA procedure?
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
Do you utilize daily enemas for patients undergoing prostate SBRT?
